Ascendis Pharma A/S Reports Third Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Ascendis Pharma (ASND) Reports Q3 Loss of EUR0.30/Share
November 12, 2015 7:10 AM ESTAscendis Pharma (NASDAQ: ASND) reported Q3 EPS of (EUR0.30), versus (EUR0.18) reported last year. Revenue for the quarter came in at EUR2.1 million, versus EUR3.3 million reported last year.
For earnings history and earnings-related data on Ascendis Pharma (ASND) click here.
... More